Regeneron's bid to acquire the bankrupt genetic testing firm 23andMe for $256 million has likely come to an end.

While the 23andMe acquisition isn't a reason to buy Regeneron, the stock's recently depressed price makes it worth a closer look. The company's former top-selling treatment, Eylea, is losing ...

A bankruptcy court approved the $305M sale of 23andMe to a nonprofit led by Anne Wojcicki, raising questions about data ...

Anne Wojcicki, founder and former CEO of 23andMe, will helm the company again after her nonprofit's purchase was approved.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Genetic testing company 23andMe can proceed with a $305 million sale to the company’s co-founder Anne Wojcicki after a U.S.

Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, retailers and other industry ...

Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals ... outlining his approval 23andMe’s sale to TTAM on Friday, Walsh acknowledged these states’ ...

States with privacy objections to the sale have until July 7 to reach a stay to appeal the case. TTAM, a nonprofit started by ...

Anne Wojcicki's nonprofit, TTAM Research Institute, has received court approval to acquire 23andMe, the genetic testing company she co-founded. The $305 million deal follows 23andMe's Chapter 11 ...

And in a memorandum opinion outlining his approval 23andMe’s sale to TTAM on Friday, Walsh acknowledged these states’ objections to the acquisition — but that noted many had since been resolved.